2009
Role for MKL1 in megakaryocytic maturation
Cheng EC, Luo Q, Bruscia EM, Renda MJ, Troy JA, Massaro SA, Tuck D, Schulz V, Mane SM, Berliner N, Sun Y, Morris SW, Qiu C, Krause DS. Role for MKL1 in megakaryocytic maturation. Blood 2009, 113: 2826-2834. PMID: 19136660, PMCID: PMC2661865, DOI: 10.1182/blood-2008-09-180596.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBlood Cell CountBone MarrowCell DifferentiationCell Line, TumorCells, CulturedDNA-Binding ProteinsGene Expression ProfilingGene Expression RegulationHumansLeukemia, Erythroblastic, AcuteMegakaryocytesMiceMice, Inbred C57BLMice, KnockoutOligonucleotide Array Sequence AnalysisOncogene Proteins, FusionPloidiesRecombinant Fusion ProteinsRNA InterferenceRNA, Small InterferingSerum Response FactorThrombocytopeniaThrombopoiesisThrombopoietinTrans-ActivatorsConceptsMegakaryoblastic leukemia 1Reduced platelet countsSerum response factorMegakaryocytic differentiationPeripheral bloodPlatelet countMKL1 expressionMegakaryoblastic leukemiaBone marrow megakaryocytesMuscle cellsPresence of thrombopoietinPhysiologic maturationHuman erythroleukemia cell lineIncreased numberMarrow megakaryocytesCell linesErythroleukemia cell lineMegakaryocytesMegakaryocytic maturationDifferentiated muscle cellsOverexpressionConcurrent increaseMuscle differentiationCellsMaturation
2007
Circulating stem cells in extremely preterm neonates
Bizzarro MJ, Bhandari V, Krause DS, Smith BR, Gross I. Circulating stem cells in extremely preterm neonates. Acta Paediatrica 2007, 96: 521-525. PMID: 17391470, DOI: 10.1111/j.1651-2227.2007.00194.x.Peer-Reviewed Original ResearchConceptsWeeks of lifePreterm neonatesNeonatal morbidityPulmonary functionPremature neonatesGestational agePeripheral bloodInitial CD34Median gestational agePulmonary function testsShort-term outcomesUmbilical cord bloodFunction testsNeonatal demographicsBirth weightCord bloodRespiratory diseaseNeonatesCell countCD34Progenitor cellsInverse correlationWeeksBloodMorbidity
2003
A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents
Lerro KA, Medoff E, Wu Y, Seropian SE, Snyder E, Krause D, Cooper DL. A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents. Bone Marrow Transplantation 2003, 32: 1113-1117. PMID: 14647264, DOI: 10.1038/sj.bmt.1704286.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsBlood Cell CountCombined Modality TherapyCyclophosphamideDatabases, FactualDexamethasoneDoxorubicinFemaleFeverGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHumansLeukapheresisMaleMiddle AgedMultiple MyelomaNeutropeniaPeripheral Blood Stem Cell TransplantationRetrospective StudiesTransplantation, AutologousVincristineConceptsMultiple myelomaEnough stem cellsCells/Autologous stem cell rescueFever/neutropeniaG-CSF beginningStem cell rescueHigh-dose chemotherapyPotential transplant candidatesMultiple myeloma patientsStem cell collectionStem cell toxicityStem cellsAggressive chemotherapyInitial therapyTransplant candidatesAgent therapyConsecutive patientsExcessive morbidityMyeloma patientsCell mobilizationCell rescuePatientsG-CSFCell collection
1999
A phase I study of paclitaxel for mobilization of peripheral blood progenitor cells
Burtness B, Psyrri A, Rose M, D’Andrea E, Staugaard-Hahn C, Henderson-Bakas M, Clark M, Mechanic S, Krause D, Snyder E, Cooper R, Abrantes J, Corringham R, Deisseroth A, Cooper D. A phase I study of paclitaxel for mobilization of peripheral blood progenitor cells. Bone Marrow Transplantation 1999, 23: 311-315. PMID: 10100573, DOI: 10.1038/sj.bmt.1701589.Peer-Reviewed Original ResearchConceptsSchedule of paclitaxelDose escalationH infusionPeripheral blood progenitor cellsDose of paclitaxelPhase I trialBlood progenitor cellsStem cell yieldStem cellsTolerable toxicityI trialInfusion scheduleDose levelsPhase IPaclitaxelDoseProgenitor cellsCells/NeuropathyFilgrastimInfusionEscalation